US biotech firm Exelixis (Nasdaq: EXEL) has joined forces with Roche (ROG: SIX) on a Phase Ib dose escalation study that will evaluate the safety and tolerability of its cabozantinib combined with a drug from the Swiss pharma giant.
Cabozantinib, Exelixis’ tyrosine kinase inhibitor (TKI), will be studied in combination with atezolizumab, Roche’s anti-PD-L1 immunotherapy, in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017;Exelixis will be the sponsor of the trial, and Roche will provide atezolizumab.
This adds to a clinical development collaboration to evaluate Cabometyx (cabozantinib) with Opdivo (nivolumab), Bristol-Myers Squibb’s (NYSE: BMY) PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab), in first-line renal cell carcinoma that Exelixis also announced yesterday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze